Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9146709 | 0.84 | KDM4E (0.36) | ALDH1A1HPGDSMN1; SMN2PIK3CGJAK3 | |
| SCHEMBL28017468 | 0.76 | ALDH1A1 (0.37) | ALDH1A1HPGDSMN1; SMN2JAK3KDM4E | |
| SCHEMBL25899164 | 0.76 | HSD17B10 (0.32) | PIK3CG | |
| SCHEMBL1436921 | 0.75 | NQO2 (0.35) | PIK3CG | |
| SCHEMBL13596901 | 0.73 | ALDH1A1 (0.35) | ALDH1A1HPGDSMN1; SMN2JAK3 | |
| SCHEMBL6239850 | 0.73 | PIK3CG (0.41) | ALDH1A1HPGDSMN1; SMN2PIK3CG | |
| SCHEMBL17779072 | 0.72 | CA2 (0.32) | PIK3CG | |
| SCHEMBL26312979 | 0.71 | PIK3CG (0.30) | PIK3CG | |
| SCHEMBL24629158 | 0.71 | ALDH1A1 (0.34) | ALDH1A1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL13313389 | 0.68 | CCR1 (0.43) | ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5385990-A | Blend of epoxy compound, amine hardener and hydroxy substituted aromatic compound | LORD CORPORATION (US) | 1995-01-31 | — | — | US | claimed |
| CN-1087367-A | Structural adhesive composition with high temperature resistance | LORD CORP (US) | 1994-06-01 | — | — | CN | claimed |
| EP-0596622-A2 | Epoxy resin structural adhesive composition having high temperature resistance | LORD CORPORATION (US) | 1994-05-11 | — | — | EP | claimed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| WO-2022272307-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022150721-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-1067096-C | Structural adhesive composition having high temperature resistance | LORD CORP (US) | 2001-06-13 | — | — | CN | disclosed |
| US-5385990-A | Blend of epoxy compound, amine hardener and hydroxy substituted aromatic compound | LORD CORPORATION (US) | 1995-01-31 | — | — | US | disclosed |
| CN-1087367-A | Structural adhesive composition with high temperature resistance | LORD CORP (US) | 1994-06-01 | — | — | CN | disclosed |
| EP-0596622-A2 | Epoxy resin structural adhesive composition having high temperature resistance | LORD CORPORATION (US) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | ALDH1A1 1027/4885HPGD 459/4885SMN1; SMN2 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.